Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: The I-CAN study

Ophthalmology

Volumn 121, Issue 9, 2014, Pages 1683-1692

  Cursiefen, Claus ^a   Viaud, Eric ^b   Bock, Felix ^a   Geudelin, Bernard ^c   Ferry, Antoine ^d   Kadlecová, Pavla ^e   Lévy, Michel ^e   Al Mahmood, Salman ^b   Colin, Sylvie ^b   Thorin, Eric ^f   Majo, François ^g   Frueh, Beatrice ^h   Wilhelm, Frank ⁱ   Meyer Ter Vehn, Tobias ^j   Geerling, Gerd ^k   Böhringer, Daniel ^l   Reinhard, Thomas ^l   Meller, Daniel ^m   Pleyer, Uwe ⁿ   Bachmann, Björn ^o   Seitz, Berthold ^p   more..

^a UNIVERSITY OF COLOGNE   (Germany)

^b Gene Signal International SA   (France)

^c Mediante GmbH   (Switzerland)

^d Laboratoires CTRS   (France)

^e Advanced Drug and Device Services SAS   (France)

^f Gene Signal International SA   (Canada)

^g HÔPITAL OPHTALMIQUE JULES GONIN   (Switzerland)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ HELIOS KLINIKEN SCHWERIN   (Germany)

^j UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^k UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^l UNIVERSITY OF FREIBURG   (Germany)

^m UNIVERSITY HOSPITAL ESSEN   (Germany)

ⁿ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^o UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^p SAARLAND UNIVERSITY   (Germany)

more..

Author keywords

Abbreviations and Acronyms; analysis of covariance; ANCOVA; CI; confidence interval; I CAN; Inhibition of CorneAl Neovascularization; insulin receptor substrate 1; intention to treat; IRS 1; ITT; per protocol; PP; QoL; quality of life; SAE; serious adverse event; TEAE; treatment emergent adverse event; VA; VAS; vascular endothelial growth factor; VEGF; visual acuity; visual analog scale

Indexed keywords

ACICLOVIR; AGANIRSEN; ANGIOGENESIS INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; CYCLOSPORIN; PLACEBO; STEROID;

ADULT; ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA TRANSPLANTATION; DISEASE COURSE; DRUG SAFETY; EVENING DOSAGE; FEMALE; GRAFT REJECTION; HUMAN; INTENTION TO TREAT ANALYSIS; KERATITIS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POPULATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT DURATION; VIRUS KERATITIS; VISUAL ACUITY;

ADULT; AGED; ANALYSIS OF VARIANCE; ANGIOGENESIS INHIBITORS; CORNEAL NEOVASCULARIZATION; CORNEAL TRANSPLANTATION; DOUBLE-BLIND METHOD; FEMALE; GRAFT REJECTION; HUMANS; KERATITIS; MALE; MIDDLE AGED; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; OPHTHALMIC SOLUTIONS; QUALITY OF LIFE; VISUAL ACUITY;

EID: 84906936272     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.03.038     Document Type: Article

References (30)

1. A.W. Taylor Ocular immune privilege Eye (Lond) 23 2009 1885 1889
2. F. Bock, K. Maruyama, and B. Regenfuss et al. Novel anti(lymph)angiogenic strategies for corneal and ocular surface disease Prog Retin Eye Res 34 2013 89 124
3. B.M. Gebhardt, and W. Shi Experimental corneal allograft rejection Immunol Res 25 2002 1 26
4. M.A. Thiel, D.J. Coster, and K.A. Williams The potential of antibody-based immunosuppressive agents for corneal transplantation Immunol Cell Biol 81 2003 93 105
5. C. Cursiefen, L. Chen, M.R. Dana, and J.W. Streilein Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology Cornea 22 2003 273 281
6. C. Cursiefen, C. Rummelt, and M. Kuchle Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization Cornea 19 2000 526 533
7. B. Bachmann, R.S. Taylor, and C. Cursiefen Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis Ophthalmology 117 2010 1300 1305
8. C. Cursiefen, J. Colin, and R. Dana et al. Consensus statement on indications for anti-angiogenic therapy in the management of corneal disease associated with neovascularisation: outcome of an expert roundtable Br J Ophthalmol 96 2012 3 9
9. C. Andrieu-Soler, M. Berdugo, and M. Doat et al. Downregulation of IRS-1 expression causes inhibition of corneal angiogenesis Invest Ophthalmol Vis Sci 46 2005 4072 4078
10. S. Al-Mahmood, S. Colin, and N. Farhat et al. Potent in vivo antiangiogenic effects of GS-101 (5′-TATCCGGAGGGCTCGCCATGCTGCT-3′), an antisense oligonucleotide preventing the expression of insulin receptor substrate-1 J Pharmacol Exp Ther 329 2009 496 504
11. F. Cloutier, M. Lawrence, and R. Goody et al. Anti-angiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administration Invest Ophthalmol Vis Sci 53 2012 1195 1203
12. European Medicines Agency. Public summary of opinion on orphan designation: Miltefosine for the treatment of Acanthamoeba keratitis. EMA/COMP/139086/2005 Rev. 4. Updated December 10, 2013. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Orphan-designation/2009/10/ WC500006373.pdf. Accessed March 13, 2014.
13. C. Cursiefen, F. Bock, and F.K. Horn et al. GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial Ophthalmology 116 2009 1630 1637
14. F. Bock, J. Onderka, and D. Hos et al. Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts Exp Eye Res 87 2008 462 470
15. Early Treatment Diabetic Retinopathy Study Research Group Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics: ETDRS report number 7 Ophthalmology 98 1991 741 756
16. F.L. Ferris III, A. Kassoff, G.H. Bresnick, and I. Bailey New visual acuity charts for clinical research Am J Opthalmol 94 1982 91 96
17. H. Dadgostar, and N. Waheed The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration Eye (Lond) 22 2008 761 767
18. M.G. Maguire, W.J. Stark, J.D. Gottsch Collaborative Corneal Transplantation Studies Research Group Risk factors for corneal graft failure and rejection in the Collaborative Corneal Transplantation Studies Ophthalmology 101 1994 1536 1547
19. K.A. Williams, D. Roder, and A. Esterman et al. Factors predictive of corneal graft survival. Report from the Australian Corneal Graft Registry Ophthalmology 99 1992 403 414
20. National Eye Institute Visual Functioning Questionnaire-25 (VFQ-25), version 2000 (interviewer administered format) 1996 Rand Health Santa Monica, CA Available at: http://www.nei.nih.gov/resources/visionfunction/vfq-ia.pdf. Accessed March 13, 2014
21. S.R. Cole, R.W. Beck, P.S. Moke Optic Neuritis Study Group The National Eye Institute Visual Function Questionnaire: experience of the ONTT Invest Ophthalmol Vis Sci 41 2000 1017 1021
22. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumad versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
23. E.S. Gragoudas, A.P. Adamis, E.T. Cunnigham Jr. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group Pegaptanib for neovascular age-related macular degeneration N Engl J Med 351 2004 2805 2816
24. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
25. B. Bachmann, R.S. Taylor, and C. Cursiefen The association between corneal neovascularization and visual acuity: a systematic review Acta Ophthalmol 91 2013 12 19
26. European Medicines Agency. European Regulatory Workshop-Ophthalmology- Summary and Report: Clinical Development, Scientific Advice and Paediatric Investigation Plans. EMA/450332/2012. August 31, 2012. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Report/2012/09/WC500131815. pdf. Accessed March 13, 2014.
27. C. Cursiefen, L. Chen, and L. Borges et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment J Clin Invest 113 2004 1040 1050
28. F. Giménez, A. Suryawanshi, and B.T. Rouse Pathogenesis of herpes stromal keratitis-a focus on corneal neovascularization Prog Retin Eye Res 33 2013 1 9
29. B. Kim, S. Lee, S. Suvas, and B.T. Rouse Application of plasmid DNA encoding IL-18 diminishes development of herpetic stromal keratitis by antiangiogenic effects J Immunol 175 2005 509 516
30. B. Kim, Q. Tang, and P.S. Biswas et al. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis Am J Pathol 165 2004 2177 2185